Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-14 (of 14 Records) |
Query Trace: Beau De Rochars V[original query] |
---|
A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis
Krentel A , Basker N , Beau de Rochars M , Bogus J , Dilliott D , Direny AN , Dubray C , Fischer PU , Ga AL , Goss CW , Hardy M , Howard C , Jambulingam P , King CL , Laman M , Lemoine JF , Mallya S , Robinson LJ , Samuela J , Schechtman KB , Steer AC , Supali T , Tavul L , Weil GJ . PLoS Negl Trop Dis 2021 15 (3) e0009002 BACKGROUND: Many countries will not reach elimination targets for lymphatic filariasis in 2020 using the two-drug treatment regimen (diethylcarbamazine citrate [DEC] and albendazole [DA]). A cluster-randomized, community-based safety study performed in Fiji, Haiti, India, Indonesia and Papua New Guinea tested the safety and efficacy of a new regimen of ivermectin, DEC and albendazole (IDA). METHODOLOGY/PRINCIPAL FINDINGS: To assess acceptability of IDA and DA, a mixed methods study was embedded within this community-based safety study. The study objective was to assess the acceptability of IDA versus DA. Community surveys were performed in each country with randomly selected participants (>14 years) from the safety study participant list in both DA and IDA arms. In depth interviews (IDI) and focus group discussions (FGD) assessed acceptability-related themes. In 1919 individuals, distribution of sex, microfilariae (Mf) presence and circulating filarial antigenemia (CFA), adverse events (AE) and age were similar across arms. A composite acceptability score summed the values from nine indicators (range 9-36). The median (22.5) score indicated threshold of acceptability. There was no difference in scores for IDA and DA regimens. Mean acceptability scores across both treatment arms were: Fiji 33.7 (95% CI: 33.1-34.3); Papua New Guinea 32.9 (95% CI: 31.9-33.8); Indonesia 30.6 (95% CI: 29.8-31.3); Haiti 28.6 (95% CI: 27.8-29.4); India 26.8 (95% CI: 25.6-28) (P<0.001). AE, Mf or CFA were not associated with acceptability. Qualitative research (27 FGD; 42 IDI) highlighted professionalism and appreciation for AE support. No major concerns were detected about number of tablets. Increased uptake of LF treatment by individuals who had never complied with MDA was observed. CONCLUSIONS/SIGNIFICANCE: IDA and DA regimens for LF elimination were highly and equally acceptable in individuals participating in the community-based safety study in Fiji, Haiti, India, Indonesia, and Papua New Guinea. Country variation in acceptability was significant. Acceptability of the professionalism of the treatment delivery was highlighted. |
Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
Dubray CL , Sircar AD , Beau de Rochars VM , Bogus J , Direny AN , Ernest JR , Fayette CR , Goss CW , Hast M , O'Brian K , Pavilus GE , Sabin DF , Wiegand RE , Weil GJ , Lemoine JF . PLoS Negl Trop Dis 2020 14 (6) e0008298 In Haiti, 22 communes still require mass drug administration (MDA) to eliminate lymphatic filariasis (LF) as a public health problem. Several clinical trials have shown that a single oral dose of ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) (IDA) is more effective than DEC plus ALB (DA) for clearing Wuchereria bancrofti microfilariae (Mf). We performed a cluster-randomized community study to compare the safety and efficacy of IDA and DA in an LF-endemic area in northern Haiti. Ten localities were randomized to receive either DA or IDA. Participants were monitored for adverse events (AE), parasite antigenemia, and microfilaremia. Antigen-positive participants were retested one year after MDA to assess treatment efficacy. Fewer participants (11.0%, 321/2917) experienced at least one AE after IDA compared to DA (17.3%, 491/2844, P<0.001). Most AEs were mild, and the three most common AEs reported were headaches, dizziness and abdominal pain. Serious AEs developed in three participants who received DA. Baseline prevalence for filarial antigenemia was 8.0% (239/3004) in IDA localities and 11.5% (344/2994) in DA localities (<0.001). Of those with positive antigenemia, 17.6% (42/239) in IDA localities and 20.9% (72/344, P = 0.25) in DA localities were microfilaremic. One year after treatment, 84% percent of persons with positive filarial antigen tests at baseline could be retested. Clearance rates for filarial antigenemia were 20.5% (41/200) after IDA versus 25.4% (74/289) after DA (P = 0.3). However, 94.4% (34/36) of IDA recipients and 75.9% (44/58) of DA recipients with baseline microfilaremia were Mf negative at the time of retest (P = 0.02). Thus, MDA with IDA was at least as well tolerated and significantly more effective for clearing Mf compared to the standard DA regimen in this study. Effective MDA coverage with IDA could accelerate the elimination of LF as a public health problem in the 22 communes that still require MDA in Haiti. |
Translating research into reality: Elimination of lymphatic filariasis from Haiti
Lammie PJ , Eberhard ML , Addiss DG , Won KY , Beau de Rochars M , Direny AN , Milord MD , Lafontant JG , Streit TG . Am J Trop Med Hyg 2017 97 71-75 Research provides the essential foundation of disease elimination programs, including the global program to eliminate lymphatic filariasis (GPELF). The development and validation of new diagnostic tools and intervention strategies, critical steps in the evolution of GPELF, required a global effort. Lymphatic filariasis research in Haiti involved many partners and was directly linked to the development of the national elimination program and to the success achieved to date. Ongoing research efforts involving many partners will continue to be important in resolving the challenges faced by the program today in its final efforts to achieve elimination. |
Partnering for impact: Integrated transmission assessment surveys for lymphatic filariasis, soil transmitted helminths and malaria in Haiti
Knipes AK , Lemoine JF , Monestime F , Fayette CR , Direny AN , Desir L , Beau de Rochars VE , Streit TG , Renneker K , Chu BK , Chang MA , Mace KE , Won KY , Lammie PJ . PLoS Negl Trop Dis 2017 11 (2) e0005387 BACKGROUND: Since 2001, Haiti's National Program for the Elimination of Lymphatic Filariasis (NPELF) has worked to reduce the transmission of LF through annual mass drug administration with diethylcarbamazine and albendazole. The NPELF reached full national coverage with MDA for LF in 2012, and by 2014, a total of 14 evaluation units (48 communes) had met WHO eligibility criteria to conduct LF transmission assessment surveys (TAS) to determine whether prevalence had been reduced to below a threshold, such that transmission is assumed to be no longer sustainable. Haiti is also endemic for malaria and many communities suffer a high burden of soil transmitted helminths (STH). Heeding the call from WHO for integration of neglected tropical diseases (NTD) activities, Haiti's NPELF worked with the national malaria control program (NMCP) and with partners to develop an integrated TAS (LF-STH-malaria) to include assessments for malaria and STH. METHODOLOGY/PRINCIPLE FINDINGS: The aim of this study was to evaluate the feasibility of using TAS surveys for LF as a platform to collect information about STH and malaria. Between November 2014 and June 2015, TAS were conducted in 14 evaluation units (EUs) including 1 TAS (LF-only), 1 TAS-STH-malaria, and 12 TAS-malaria, with a total of 16,655 children tested for LF, 14,795 tested for malaria, and 298 tested for STH. In all, 12 of the 14 EUs passed the LF TAS, allowing the program to stop MDA for LF in 44 communes. The EU where children were also tested for STH will require annual school-based treatment for STH to maintain reduced STH levels. Finally, only 12 of 14,795 children tested positive for malaria by RDT in 38 communes. CONCLUSIONS/SIGNIFICANCE: Haiti's 2014-2015 Integrated TAS surveys provide evidence of the feasibility of using the LF TAS as a platform for integration of assessments for STH and or malaria. |
Malaria vector research and control in Haiti: a systematic review
Frederick J , Saint Jean Y , Lemoine JF , Dotson EM , Mace KE , Chang M , Slutsker L , Le Menach A , Beier JC , Eisele TP , Okech BA , Beau de Rochars VM , Carter KH , Keating J , Impoinvil DE . Malar J 2016 15 (1) 376 BACKGROUND: Haiti has a set a target of eliminating malaria by 2020. However, information on malaria vector research in Haiti is not well known. This paper presents results from a systematic review of the literature on malaria vector research, bionomics and control in Haiti. METHODS: A systematic search of literature published in French, Spanish and English languages was conducted in 2015 using Pubmed (MEDLINE), Google Scholar, EMBASE, JSTOR WHOLIS and Web of Science databases as well other grey literature sources such as USAID, and PAHO. The following search terms were used: malaria, Haiti, Anopheles, and vector control. RESULTS: A total of 132 references were identified with 40 high quality references deemed relevant and included in this review. Six references dealt with mosquito distribution, seven with larval mosquito ecology, 16 with adult mosquito ecology, three with entomological indicators of malaria transmission, eight with insecticide resistance, one with sero-epidemiology and 16 with vector control. In the last 15 years (2000-2015), there have only been four published papers and three-scientific meeting abstracts on entomology for malaria in Haiti. Overall, the general literature on malaria vector research in Haiti is limited and dated. DISCUSSION: Entomological information generated from past studies in Haiti will contribute to the development of strategies to achieve malaria elimination on Hispaniola. However it is of paramount importance that malaria vector research in Haiti is updated to inform decision-making for vector control strategies in support of malaria elimination. |
Haiti National Program for the Elimination of Lymphatic Filariasis - a model of success in the face of adversity
Oscar R , Lemoine JF , Direny AN , Desir L , Beau de Rochars VE , Poirier MJ , Varghese A , Obidegwu I , Lammie PJ , Streit TG , Milord MD . PLoS Negl Trop Dis 2014 8 (7) e2915 Lymphatic filariasis (LF) is a mosquito-borne parasitic infection that causes lymphedema, elephantiasis, and hydrocele. Haiti is one of only four countries left in the Americas where transmission of lymphatic filariasis still occurs. The National Program to Eliminate LF (NPELF) was started in Haiti in 2000, and by 2005 a population of 1.6 million people in 24 communes, including the majority of high-prevalence communes, was targeted at least once for mass drug administration (MDA). An interruption in external funding at the end of 2005 paralyzed the program, but with new donor support the NPELF was able to scale up to achieve full geographic coverage, reaching more than 8 million people in 2012. The LF program in Haiti has faced many challenges, including political crises, hurricanes, a devastating earthquake, and a deadly cholera outbreak in the earthquake's aftermath. Despite these challenges, the NPELF and partners have persisted, and now the program is integrated with soil-transmitted helminth (STH) control, is national in scope, and provides appropriate supportive care for persons suffering from LF morbidity. Haiti serves as a model for successful program implementation in countries affected by political and social challenges and natural disasters. |
A longitudinal analysis of the effect of mass drug administration on acute inflammatory episodes and disease progression in lymphedema patients in Leogane, Haiti
Eddy BA , Blackstock AJ , Williamson JM , Addiss DG , Streit TG , Beau de Rochars VM , Fox LM . Am J Trop Med Hyg 2014 90 (1) 80-8 We conducted a longitudinal analysis of 117 lymphedema patients in a filariasis-endemic area of Haiti during 1995-2008. No difference in lymphedema progression between those who received or did not receive mass drug administration (MDA) was found on measures of foot (P = 0.24), ankle (P = 0.87), or leg (P = 0.46) circumference; leg volume displacement (P = 0.09), lymphedema stage (P = 0.93), or frequency of adenolymphangitis (ADL) episodes (P = 0.57). Rates of ADL per year were greater after initiation of MDA among both groups (P < 0.01). Nevertheless, patients who received MDA reported improvement in four areas of lymphedema-related quality of life (P ≤ 0.01). Decreases in foot and ankle circumference and ADL episodes were observed during the 1995-1998 lymphedema management study (P ≤ 0.01). This study represents the first longitudinal, quantitative, leg-specific analysis examining the clinical effect of diethylcarbamazine on lymphedema progression and ADL episodes. |
Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions
Chitnis AS , Caruthers PS , Rao AK , Lamb J , Lurvey R , Beau De Rochars V , Kitchel B , Cancio M , Torok TJ , Guh AY , Gould CV , Wise ME . Infect Control Hosp Epidemiol 2012 33 (10) 984-92 OBJECTIVE: To describe a Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) outbreak and interventions to prevent transmission. DESIGN, SETTING, AND PATIENTS: Epidemiologic investigation of a CRE outbreak among patients at a long-term acute care hospital (LTACH). METHODS: Microbiology records at LTACH A from March 2009 through February 2011 were reviewed to identify CRE transmission cases and cases admitted with CRE. CRE bacteremia episodes were identified during March 2009-July 2011. Biweekly CRE prevalence surveys were conducted during July 2010-July 2011, and interventions to prevent transmission were implemented, including education and auditing of staff and isolation and cohorting of CRE patients with dedicated nursing staff and shared medical equipment. Trends were evaluated using weighted linear or Poisson regression. CRE transmission cases were included in a case-control study to evaluate risk factors for acquisition. A real-time polymerase chain reaction assay was used to detect the bla(KPC) gene, and pulsed-field gel electrophoresis was performed to assess the genetic relatedness of isolates. RESULTS: Ninety-nine CRE transmission cases, 16 admission cases (from 7 acute care hospitals), and 29 CRE bacteremia episodes were identified. Significant reductions were observed in CRE prevalence (49% vs 8%), percentage of patients screened with newly detected CRE (44% vs 0%), and CRE bacteremia episodes (2.5 vs 0.0 per 1,000 patient-days). Cases were more likely to have received beta-lactams, have diabetes, and require mechanical ventilation. All tested isolates were KPC-producing K. pneumoniae, and nearly all isolates were genetically related. CONCLUSION: CRE transmission can be reduced in LTACHs through surveillance testing and targeted interventions. Sustainable reductions within and across healthcare facilities may require a regional public health approach. |
A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis
Gass K , Beau de Rochars MV , Boakye D , Bradley M , Fischer PU , Gyapong J , Itoh M , Ituaso-Conway N , Joseph H , Kyelem D , Laney SJ , Legrand AM , Liyanage TS , Melrose W , Mohammed K , Pilotte N , Ottesen EA , Plichart C , Ramaiah K , Rao RU , Talbot J , Weil GJ , Williams SA , Won KY , Lammie P . PLoS Negl Trop Dis 2012 6 (1) e1479 Successful mass drug administration (MDA) campaigns have brought several countries near the point of Lymphatic Filariasis (LF) elimination. A diagnostic tool is needed to determine when the prevalence levels have decreased to a point that MDA campaigns can be discontinued without the threat of recrudescence. A six-country study was conducted assessing the performance of seven diagnostic tests, including tests for microfilariae (blood smear, PCR), parasite antigen (ICT, Og4C3) and antifilarial antibody (Bm14, PanLF, Urine SXP). One community survey and one school survey were performed in each country. A total of 8,513 people from the six countries participated in the study, 6,443 through community surveys and 2,070 through school surveys. Specimens from these participants were used to conduct 49,585 diagnostic tests. Each test was seen to have both positive and negative attributes, but overall, the ICT test was found to be 76% sensitive at detecting microfilaremia and 93% specific at identifying individuals negative for both microfilariae and antifilarial antibody; the Og4C3 test was 87% sensitive and 95% specific. We conclude, however, that the ICT should be the primary tool recommended for decision-making about stopping MDAs. As a point-of-care diagnostic, the ICT is relatively inexpensive, requires no laboratory equipment, has satisfactory sensitivity and specificity and can be processed in 10 minutes-qualities consistent with programmatic use. Og4C3 provides a satisfactory laboratory-based diagnostic alternative. |
Travel health alert notices and Haiti cholera outbreak, Florida, USA, 2011
Selent MU , McWhorter A , Beau De Rochars VM , Myers R , Hunter DW , Brown CM , Cohen NJ , Molinari NA , Warwar K , Robbins D , Heiman KE , Newton AE , Schmitz A , Oraze MJ , Marano N . Emerg Infect Dis 2011 17 (11) 2169-2171 To enhance the timeliness of medical evaluation for cholera-like illness during the 2011 cholera outbreak in Hispaniola, printed Travel Health Alert Notices (T-HANs) were distributed to travelers from Haiti to the United States. Evaluation of the T-HANs' influence on travelers' health care-seeking behavior suggested T-HANs might positively influence health care-seeking behavior. |
Epidemic cholera in a crowded urban environment, Port-au-Prince, Haiti
Dunkle SE , Mba-Jonas A , Loharikar A , Fouche B , Peck M , Ayers T , Archer WR , Beau De Rochars VM , Bender T , Moffett DB , Tappero JW , Dahourou G , Roels TH , Quick R . Emerg Infect Dis 2011 17 (11) 2143-2146 We conducted a case-control study to investigate factors associated with epidemic cholera. Water treatment and handwashing may have been protective, highlighting the need for personal hygiene for cholera prevention in contaminated urban environments. We also found a diverse diet, a possible proxy for improved nutrition, was protective against cholera. |
Knowledge, attitudes, and practices related to treatment and prevention of cholera, Haiti, 2010
Beau De Rochars VEM , Tipret J , Patrick M , Jacobson L , Barbour KE , Berendes D , Bensyl D , Frazier C , Domercant JW , Archer R , Roels T , Tappero JW , Handzel T . Emerg Infect Dis 2011 17 (11) 2158-2161 In response to the recent cholera outbreak, a public health response targeted high-risk communities, including resource-poor communities in Port-au-Prince, Haiti. A survey covering knowledge and practices indicated that hygiene messages were received and induced behavior change, specifically related to water treatment practices. Self-reported household water treatment increased from 30.3% to 73.9%. |
A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti
Boyd A , Won KY , McClintock SK , Donovan CV , Laney SJ , Williams SA , Pilotte N , Streit TG , Beau de Rochars MV , Lammie PJ . PLoS Negl Trop Dis 2010 4 (3) e640 Seven rounds of mass drug administration (MDA) have been administered in Leogane, Haiti, an area hyperendemic for lymphatic filariasis (LF). Sentinel site surveys showed that the prevalence of microfilaremia was reduced to <1% from levels as high as 15.5%, suggesting that transmission had been reduced. A separate 30-cluster survey of 2- to 4-year-old children was conducted to determine if MDA interrupted transmission. Antigen and antifilarial antibody prevalence were 14.3% and 19.7%, respectively. Follow-up surveys were done in 6 villages, including those selected for the cluster survey, to assess risk factors related to continued LF transmission and to pinpoint hotspots of transmission. One hundred houses were mapped in each village using GPS-enabled PDAs, and then 30 houses and 10 alternates were chosen for testing. All individuals in selected houses were asked to participate in a short survey about participation in MDA, history of residence in Leogane and general knowledge of LF. Survey teams returned to the houses at night to collect blood for antigen testing, microfilaremia and Bm14 antibody testing and collected mosquitoes from these communities in parallel. Antigen prevalence was highly variable among the 6 villages, with the highest being 38.2% (Dampus) and the lowest being 2.9% (Corail Lemaire); overall antigen prevalence was 18.5%. Initial cluster surveys of 2- to 4-year-old children were not related to community antigen prevalence. Nearest neighbor analysis found evidence of clustering of infection suggesting that LF infection was focal in distribution. Antigen prevalence among individuals who were systematically noncompliant with the MDAs, i.e. they had never participated, was significantly higher than among compliant individuals (p<0.05). A logistic regression model found that of the factors examined for association with infection, only noncompliance was significantly associated with infection. Thus, continuing transmission of LF seems to be linked to rates of systematic noncompliance. |
Assessing the impact of a missed mass drug administration in Haiti
Won KY , Beau de Rochars M , Kyelem D , Streit TG , Lammie PJ . PLoS Negl Trop Dis 2009 3 (8) e443 Lymphatic filariasis (LF) is a disfiguring and debilitating parasitic disease that is endemic in 81 countries, placing a staggering 1.3 billion people at risk for filarial infection [1]. In 1997, the World Health Assembly resolved to eliminate LF as a public health problem, and in 2000, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was officially launched. Coupled with the development of essential diagnostic tools, the primary strategy devised to achieve LF elimination was to implement annual mass drug administration (MDA) using combinations of albendazole plus either diethylcarbamazine or ivermectin for at-risk populations [2]. These single-dose treatment regimens were chosen for their ability to significantly reduce microfilaremia for periods of up to one year, limiting the transmission potential. Through generous donations of drugs from GlaxoSmithKline and Merck & Co., the global program began its first treatments in 2000. Since then, 48 of the 81 endemic countries have implemented MDA and almost 2 billion treatments have been provided [1]. These treatments have led to dramatic reductions in microfilaremia and have provided significant collateral benefit by reducing soil-transmitted helminthiasis [3],[4]. Furthermore, more than 6 million cases of hydrocele and 4 million cases of lymphedema have been prevented in the last eight years, translating into more than 32 million disability-adjusted life years averted [3]. Through the efforts of a national program, China became the first country to declare the elimination of LF as a public health problem, and in March 2008, the Republic of Korea also made a similar announcement [1]. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure